CoChat

Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?

Open access
O'Malley, Grace, Heijltjes, Madelon, Houston, Aileen M., Rani, Sweta, Ritter, Thomas, Egan, Laurence J., Ryan, Aideen E. · 2016 · Oncotarget
Cited by 71

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

// Grace O’Malley 1,2 , Madelon Heijltjes 3 , Aileen M. Houston 4 , Sweta Rani 1 , Thomas Ritter 1 , Laurence J. Egan 2 and Aideen E. Ryan 1,2 1 Regenerative Medicine Institute (REMEDI), National Centre for Biomedical Engineering Science (NCBES) NUI, Galway, Ireland 2 Discipline of Pharmacology and Therapeutics, Translational Research Facility, National University of Ireland, Galway, Ireland 3 Leiden University Medical Centre, Leiden, The Netherlands 4 Department of Medicine, University College Cork, Ireland Correspondence to: Aideen E. Ryan, email: // Keywords : mesenchymal stromal cells, tumour microenvironment, colorectal cancer, immunosuppression, immunomodulation Received : February 09, 2016 Accepted : July 09, 2016 Published : August 17, 2016 Abstract The tumour microenvironment (TME) is an important factor in determining the growth and metastasis of colorectal cancer, and can aid tumours by both establishing an immunosuppressive milieu, allowing the tumour avoid immune clearance, and by hampering the efficacy of various therapeutic regimens. The tumour microenvironment is composed of many cell types including tumour, stromal, endothelial and immune cell populations. It is widely accepted that cells present in the TME acquire distinct functional phenotypes that promote tumorigenesis. One such cell type is the mesenchymal stromal cell (MSC). Evidence suggests that MSCs exert effects in the colorectal tumour microenvironment including the promotion of angiogenesis, invasion and metastasis. MSCs immunomodulatory capacity may represent another largely unexplored central feature of MSCs tumour promoting capacity. There is considerable evidence to suggest that MSCs and their secreted factors can influence the innate and adaptive immune responses. MSC-immune cell interactions can skew the proliferation and functional activity of T-cells, dendritic cells, natural killer cells and macrophages, which could favour tumour growth and enable tumours to evade immune cell clearance. A better understanding of the interactions between the malignant cancer cell and stromal components of the TME is key to the development of more specific and efficacious therapies for colorectal cancer. Here, we review and explore MSC- mediated mechanisms of suppressing anti-tumour immune responses in the colon tumour microenvironment. Elucidation of the precise mechanism of immunomodulation exerted by tumour-educated MSCs is critical to inhibiting immunosuppression and immune evasion established by the TME, thus providing an opportunity for targeted and efficacious immunotherapy for colorectal cancer growth and metastasis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.11354

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

Metadata

Authors
O'Malley, G., Heijltjes, M., Houston, A. M., Rani, S., Ritter, T., Egan, L. J., & Ryan, A. E.
Venue
Oncotarget
Published
2016-08-17
Volume
7
Issue
37
Pages
60752-60774
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2515851707
Cited by
71
References
33
FWCI
3.56
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.